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Abstract
Background: Lung cancer is the leading cause of cancer deaths worldwide, with a five-year overall survival rate of only 15%.
Cancerous inhibitor of PP2A (CIP2A) is a human oncoprotein inhibiting PP2A in many human malignancies. However,
whether CIP2A can be a new drug target for lung cancer is largely unclear.
Methodology/PrincipalFindings:Normal and malignantlungtissues werederivedfrom 60lungcancer patientsfrom southern
China. RT-PCR, Western blotting and immunohistochemistry were used to evaluate the expression of CIP2A. We found that
among the 60 patients, CIP2A was undetectable or very low in paratumor normal tissues, but was dramatically elevated in
tumor samples in 38 (63.3%) patients. CIP2A overexpression was associated with cigarette smoking. Silencing CIP2A by siRNA
inhibited theproliferationand clonogenicactivityoflungcancercells.Intriguingly, wefound anaturalcompound,rabdocoetsin
B which is extracted from a Traditional Chinese Medicinal herb Rabdosia coetsa, could induce down-regulation of CIP2A and
inactivation of Akt pathway, and inhibit proliferation and induce apoptosis in a variety of lung cancer cells.
Conclusions/Significance: Our findings strongly indicate that CIP2A could be an effective target for lung cancer drug
development, and the therapeutic potentials of CIP2A-targeting agents warrant further investigation.
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Introduction
Nearly 1.5 million people were diagnosed with lung cancer and 1.4
million people were estimated to die from it in 2007 [1]. The two major
forms of lung cancer are non–small cell lung cancer (NSCLC) and
small cell lung cancer (SCLC). About 85% of lung cancers are
NSCLC, which can be divided into three major histological subtypes:
squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma.
SCLC represents about 15% of lung cancers [2]. Smoking causes all
types of lung cancer but is most strongly linked with SCLC and
squamous-cell carcinoma; adenocarcinoma is the most common type
in patients who have never smoked [2]. Current treatment is
determined by the histologic type of lung cancer and stage at diagnosis,
including surgery, platinum doublet therapy, radiation therapy and
targeted therapy. Unfortunately, the prognosis of lung cancer is poor
with a only 15% of five-year overall survival rate for all stages
combined [1]. Therefore, there is an urgent need to identify more
effective molecular targets and new targeted therapies for lung cancer.
Cancerous Inhibitor of PP2A (CIP2A) is a human oncoprotein
that stabilizes c-Myc by inhibiting protein phosphatase 2A (PP2A)-
mediated dephosphorylationofMYCatserine62[3].Inadditionto
inhibiting the degradation of c-Myc, CIP2A appears to be regulated
in a positive feedback loop with c-Myc by promoting each other’s
expression [4]. CIP2A is over-expressed in human neck and head
carcinomas, colon, breast, and gastric cancer, and is inversely
correlated with disease outcome in gastric cancer [3–7]. However,
whether CIP2A could be a new drug target for cancers is not fully
investigated, and the anti-tumor activity of CIP2A-targeting agents
remains largely unknown. We studied the expression of CIP2A in
lung cancer and screened for lead compounds that could target
CIP2A [8]. Here we show that CIP2A is markedly upregulated in
lung cancer tumors compared to patient-matched adjacent normal
lung tissues, and report that a natural compound which triggers
downregulation of CIP2A exhibits significant antitumor activity in
NSCLC cell lines.
Results
CIP2A is over-expressed in lung cancer and is associated
with cigarette smoking
We tested the expression of CIP2A at protein level in
nonmalignant and malignant cells, and found that CIP2A was
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20159highly expressed in lung cancer cell lines (A549, H1975, 95D and
L78) compared to normal human embryonic lung fibroblasts (HLF
and MRC5) and normal human bronchial epithelial cells
(HBEpiC) (Figure 1A). We then analyzed CIP2A in 60 lung
cancer samples from patients came from southern China whose
baseline characteristics were listed in Table 1. We showed that
CIP2A was over-expressed in 38 (63.3%) tumor specimens assayed
by western blotting (Figure 1B). However, in the 60 patient-
matched adjacent normal lung tissues, CIP2A was undetectable in
57 (95%) samples, and was weakly expressed in 3 (5%) specimens
where its expression was much lower than that in tumor samples of
the same patients. In samples from 2 patients with inflammatory
pseudotumor, CIP2A was not detected in both the pseudotumor
and adjacent lung tissues (Figure 1C). Immunohistochemistry
Figure 1. CIP2A is over-expressed in human lung cancer. (A): Western blot analysis of CIP2A in human lung cancer cells (A549, H1975, 95D and
L78), embryonic lung fibroblast cells (HLF and MRC-5), and normal human bronchial epithelial cells (HBEpiC). (B): Western blot analyses of CIP2A
protein in primary lung tumors (T) and adjacent normal lung tissues (N). b-Actin is used as a loading control. Representative results are shown and
numbers are referred to individual patients. (C): Western blot analyses of CIP2A protein in inflammatory pseudotumor (P) and adjacent normal lung
tissues (N). b-Actin is used as a loading control. (D): Representative images (left panel) and score (right panel) of immunohistochemistry staining for
CIP2A expression in primary lung tumors (T) and adjacent normal lung tissues (N). (E): RT-PCR analyses of CIP2A mRNA in primary lung tumors (T) and
adjacent normal lung tissues (N). GAPDH is employed as a loading control. Representative results are shown and numbers are referred to individual
patients.
doi:10.1371/journal.pone.0020159.g001
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higher immunoreactivity score in tumor samples in 26 out of 39
patients (66.7%) tested (Figure 1D). At mRNA level, CIP2A was
also over-expressed in lung tumor tissues compared to normal lung
tissues in 39 of 58 (67.2%) patients tested (Figure 1E). Taken
together, CIP2A is dramatically elevated in lung cancer tumor
samples compared to paired normal lung tissues.
CIP2A overexpression is associated with cigarette
smoking
We analyzed the correlation between CIP2A overexpression and
some clinicopathologic variables. The data demonstrated that CIP2A
overexpression in lung cancer was significantly correlated with
histologic type of squamous cell carcinoma (p=0.003) and male
gender (p=0.008) (Table 1) that were shown to strongly link with
cigarette smoking [2,9]. Moreover, our data clearly showed that the
high expression of CIP2A was associated with smoker patients
(p=0.004). No significant difference in the CIP2A status was
observed according to the pathological stage (p=0.639) and age
(0.082) (Table 1). In an attempt to clarify the most significant factors
related to CIP2A overexpression, the multivariate analyses were
performed, and the multivariate logistic regression analysis (Table 2)
demonstrated that cigarette smoking was the only significant variable
associated with CIP2A overexpression in lung cancer (p=0.008).
The nitrosamine 4-(methylnitro-samino)-1-(3-pyridyl)-1-buta-
none, or the nicotine-derived nitrosamine ketone (NNK), is a
key ingredient of tobacco smoke carcinogen which systemically
induces tumors of the lung in rats, mice, and hamsters and also
plays a major role in lung carcinogenesis [10,11]. We then
investigated whether NNK could directly induce upregulation of
CIP2A or not. To do this, HBEpiC (Figure 2A) and BEAS-2B
(Figure 2B) bronchial epithelial cells were exposed to NNK at
indicated concentration for indicated time points, lysed, and
western blot was performed to analyze the expression of CIP2A.
The results showed that treatment with NNK at 0.1 to 10 mM for
up to 18 days could not perturb CIP2A expression (Figure 2, A
and B). In this study, we did not test the long-term effect of NNK
on CIP2A expression in vitro or in vivo.
CIP2A is required for lung cancer cells growth and
transformation
CIP2A specific siRNA was employed to evaluate its roles in lung
cancer pathogenesis, and the results showed that as compared to
negative control (NC), CIP2A silencing (Figure 3A) led to
inhibition of clonogenic activity of A549 cells, detected by foci
formation (Figure 3, B and C) and soft agar colony formation
(Figure 3, D and E) assays [3]. These phenomena were confirmed
by results of CIP2A silencing in L78 cells (Figure S1, A through E).
Next, A549 cells were transfected with NC or CIP2A-specific
siRNA (Figure 3F), and injected subcutaneously into the right and
left flanks of 8 nude mice respectively, and tumor volumes were
estimated every two days [12]. Interestingly, CIP2A-specific
siRNA significantly inhibited tumor growth as compared to NC-
siRNA (Figure 3, G through I). Together, these data indicate that
CIP2A is essential to lung cancer proliferation and tumorigenesis,
and could be an effective therapeutic target.
Rabdocoetsin B is a CIP2A-targeting natural compound
Our central goal was to identify new drug targets and provide
lead compounds for drug development. We screened for CIP2A-
targeting small molecules by analyzing their effects on CIP2A
expression, and identified a natural compound extracted from a
Chinese medicinal herbal Rabdosia coetsa, rabdocoetsin B [13,14]
(Figure 4A), could downregulate CIP2A at protein level at 5 to
20 mM in A549 cells (Figure 4B). In H1975 cells, Rabdocoetsin B
also triggered downregulation of CIP2A at 5 to 10 mM (Figure 4C).
We analyzed the mechanism of CIP2A down-regulation caused by
Rabdocoetsin B, and found that rabdocoetsin B significantly
inhibited the transcription of CIP2A in a dose-dependent manner
(Figure 4D) assessed by real-time RT-PCR.
Rabdocoetsin B inhibits CIP2A-modulated
phosphorylated Akt
In hepatocellular carcinoma cells, CIP2A up-regulates phospho-
Akt (pAkt) and decreases Akt-related PP2A activity, whereas
silencing CIP2A re-activates PP2A [15]. Since Akt is constitutively
active in lung cancer cells and promotes cellular survival and
resistance to chemotherapy and radiation [16,17], we examined
Table 1. Baseline demographic characteristics of patients
underwent western blot analysis of CIP2A.
Characteristics Cases, n CIP2A-high, n (%) P* value
Gender
male 40 30 (75) 0.008
female 20 8 (40)
Age
,65 44 25 (56.8) 0.082
.=65 16 13 (81.2)
Smoking
smoker 36 28 (77.8) 0.004
non-smoker 24 10 (41.7)
Histology
adenocarcinoma 35 17 (48.6) 0.003**
squamous-cell carcinoma 19 17 (89.5)
adenosquamouscarcinoma 5 3 (60)
small cell lung cancer 1 1 (100)
TNM stage
IA 3 2 (66.7) 0.639
IIB 22 11 (50)
IIA 2 1 (50)
IIB 6 5 (83.3)
IIIA 19 12 (63.2)
IIIB 1 1 (100)
IV 3 3 (100)
NA 4 3 (75)
*Chi-Square Test;
**Adenocarcinoma versus Squamous-cell carcinoma; NA, unknown.
doi:10.1371/journal.pone.0020159.t001
Table 2. Multivariate logistic analyses of the association
between CIP2A high expression and clinic characteristics.
Variable Odds ratio 95.0% Confidence Interval P value
Smoking 5.330 1.537–18.487 0.008
Histology 2.186 0.865–5.524 0.098
TNM stage 1.349 0.958–1.899 0.087
doi:10.1371/journal.pone.0020159.t002
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CIP2A silencing by specific siRNA resulted in down-regulation of
pAkt but not pERK, PCNA, b-catenin, EGFR or Src (Figure 5A).
We then investigated whether rabdocoetsin B could modulate the
expression of pAkt, and found that treatment with rabdocoetsin B
at 5 to 10 mM also down-regulated pAkt in A549 (Figure 5B) and
H1975 (Figure 5C) cells. We further showed that in H1975 cells
upon rabdocoetsin B at 10 mM, CIP2A was markedly downreg-
ulated in 6 to 12 h and became undetectable in 48 h (Figure 5D),
while pAKT was decreased in 18 h (Figure 5D). These results
were confirmed in A549 cells treated with rabdocoetsin B
(Figure 5E), indicating that this compound can inhibit the
CIP2A-Akt pathway in lung cancer.
Effects of Rabdocoetsin B on lung cancer cells
We evaluated the effects of rabdocoetsin B on lung cancer cells
expressing wide-type (WT) or mutant EGFR. We showed that
rabdocoetsin B exhibited significant cytotoxic effects on A549, NCI-
H1975, HCC827, SPC-A-1, GLC-82, L78 and 95D lung cancer
cell lines (Figure 6, A and B). Rabdocoetsin B induced apoptosis of
A549 cells (Figure 6C) with activation of casp-8 and casp-9 and
cleavage of PARP (Figure 6D). Rabdocoetsin B also caused
activation of casp-8 and casp-9 and cleavage of PARP in NCI-
H1975 cells (Figure 6E). These results indicate that rabdocoetsin B
inhibits proliferation and induces apoptosis of lung cancer cells via
activating the endogenous and exogenous apoptosis pathways.
Discussion
CIP2A is an auto-antigen [7] that is over-expressed in human
neoplasms [3–7,18–21]. Peng [22] showed that in American-based
patients, CIP2A is increased in 61 of the 72 (84.7%) lung cancer
tissue specimens, which is significantly higher than in normal lung
tissues (14.3%, 9/63). Recently, Dong et al [23] reported that in
29 patients from Northern China, CIP2A is over-expressed at
mRNA level in 24 cases (82.7%) in tumor samples compared with
their corresponding normal tissues; CIP2A protein (detected by
immunohistochemistry) is found to be over-expressed in 72.2% of
90 lung cancer samples and correlated with poor survival. We test
CIP2A expression in 60 patients from Southern China [8], and
report that CIP2A is drastically increased in 63.3% (detected by
western blotting) or 67.2% (at mRNA level) of tumor specimens
compared to adjacent normal tissues (Figure 1).
We show for the first time that CIP2A overexpression is
associated with cigarette smoking. In the 60 lung cancer patients
examined in this study, 28 of 36 (77.8%) smoker patients show
increased expression of CIP2A in the tumor samples compared to
their adjacent normal specimens, whereas 10 of 24 (41.7%)
nonsmoker cases exhibit up-regulated CIP2A at protein level
(p=0.004) (Table 1). Currently smoking continues to be more
prevalent among men (63%) than women (3.8%) [24]. We report
here that CIP2A is over-expressed in 30/40 (75%) and 8/20 (40%)
in men and women patients (p=0.008) (Table 1), respectively. We
also find that CIP2A is elevated in 17/19 (89.5%) patients with
squamous cell carcinoma, whereas 17/35 (48.6%) patients with
adenocarcinoma have over-expressed CIP2A (p=0.003) (Table 1).
The multivariate logistic regression analysis clearly demonstrates
that smoking is the only significant variable associated with CIP2A
overexpression in lung cancer in our setting (p=0.008) (Table 2).
While the overall smoking rate in the North and Northeast sectors is
higher than that in the South and East of China, the prevalence of
environmental tobacco smoke exposure among nonsmokers in
Northern China is significantly higher than that in nonsmokers in
Southern China [24,25]. These may contribute to the difference in
CIP2A expression betweenpatients inour setting and Dong’sreport
[23]. Tobacco smoke which causes approximately 5–6 million
deaths per year and 31% and 6% of all lung cancer deaths in
middle-aged men and women respectively [26], can induce genetic
and epigenetic changes and reduce DNA repair capacity [2]. Zhao
etal[27] recentlyshowedthatinhumangastriccell lines,Helicobacter
pylori infection can induce CIP2A expression via bacterial
oncoprotein CagA-caused activation of the Src and MEK/ERK
signal pathways. Though NNK (0.1 to 50 mM) fails to upregulate
CIP2A in HBEpiC and BEAS-2B cells in up to 18 days in our study
(Figure 2),we cannot exclude the possibility that NNK may perturb
the expression of the oncoprotein in a longer exposure time course,
and this hypothesis warrants further investigation.
CIP2A is critical for lung cancer cell growth, since CIP2A
knockdown by specific siRNA results in significant inhibition of cell
proliferation and transformation in vitro and in vivo (Figure 3 and
Figure S1). These data indicate that CIP2A could be an attractive
target for novel anti-lung cancer drugs. Interestingly, we identify a
naturalcompoundrabdocoetsinB, candown-regulateCIP2Aprotein
in lung cancer cells (Figure 4, A through C) by inhibiting its
expression at mRNA level (Figure 4D). Studies show that CIP2A can
up-regulate pAkt [15], and our results confirm that CIP2A silencing
can decrease pAkt (Figure 5A). We further show that rabdocoetsin B
alsoinhibits pAkt(Figure 5, B throughE). Rabdocoetsin B inhibits the
growth and induces apoptosis of a variety of lung cancer cells




Use of the samples was approved by the Institutional Review
Board of Institute of Zoology, Chinese Academy of Sciences and
Figure 2. Effects of NNK on CIP2A expression. (A): HBEpiC cells
were treated with NNK at various concentrations for indicated time
points, and western blot was performed to analyze CIP2A expression.
(B): BEAS-2B cells were treated with NNK at indicated concentrations for
indicated time points, and western blot was conducted to analyze
CIP2A expression. 0.05% and 0.1% DMSO were used as a solvent control
corresponding to 5 mM and 10 mM NNK, respectively.
doi:10.1371/journal.pone.0020159.g002
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PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e20159Figure 3. CIP2A is required for lung cancer cells’ growth and transformation. (A): Western blot analysis of CIP2A protein expression in A549
cells 72 h after transfection with negative control (NC) or CIP2A-specific siRNA. (B and C): Flat plate clone formation assay for the clonogenic activity
of A549 cells 72 h after transfection with NC or CIP2A-specific siRNA. (B): representative light miscroscopy images. (C): Quantitation of foci counting.
Shown is mean+SD of four independent experiments. (D and E): Soft-agar colony formation assay for A549 cells transfected with NC or CIP2A-specific
siRNA. (D): representative light miscroscopy images. (E): Quantitation of foci counting. (F): Western blot analysis of CIP2A protein in A549 cells
transfected with NC or CIP2A-specific siRNA for 72 h. (G): Nude mice injected subcutaneously with A549 cells transfected with NC or CIP2A-specific
siRNA. (H): The tumor growth curve for the experiment shown in (G). Shown is mean+SD of the mean tumor volumes. (I) Image of xenograft tumors
obtained from mice shown in (G). * p,0.01, Student’s t test.
doi:10.1371/journal.pone.0020159.g003
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adjacent normal tissue samples were obtained with written
informed consent from patients at the Cancer Hospital, Sun
Yat-Sen University. For RT-PCR analysis, tissue specimens were
ground in liquid nitrogen-cooled mortar, RNA was extracted using
the Trizol (Invitrogen), and RT-PCR experiments were performed
using PrimeScriptH One Step RT-PCR Kit Ver.2 (TaKaRa)
according to the manufacturer’s protocol. The sequences of
primers used for CIP2A are as follows: forward 59-CCATATGCT-
CACTCAGATGATGT-39,_reverse 59-GTGTATCATCTCCA-
CAGAGAGTT-39 [5].
For Western blot assay, tissue specimens were ground in liquid
nitrogen-cooled mortar, tissue powder was suspended in lysis
buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% triton X-
100, 1% sodium deoxycholate, 0.1% SDS, 1 mM Na3VO4,1m M
NaF, 1 mM EDTA, 1 mM PMSF, complete protease inhibitor
cocktail) and cleared by centrifugation. Equal amounts of samples
were separated by SDS-PAGE, transferred to nitrocellulose and
immunoblotted with anti-CIP2A or anti-b-actin antibody.
Immunohistochemical assay and scoring of immunoreactivity
were performed as described [28]. Formalin-fixed, paraffin-
embedded lung cancer tissue specimens (5 mm) were deparaffi-
nized and subjected to a heat-induced epitope retrieval step for
2m i n . T h e H 2O2 (3%) was used to block endogenous
peroxidase activity for 10 min. The sections were then washed
with PBS. The rabbit polyclonal anti-CIP2A antibody was
applied to the slides at a dilution of 1:500 at 4uCo v e r n i g h t .
Detection was achieved with the Immunohistochemistry kit (pv-
6001) (Zhongshan Golden Bridge Biotechnology Co., Ltd,
Beijing, China) according to the manufacturer’s protocol.
Sections were colored with 3, 39-diaminobenzidine (DAB) and
counterstained with hematoxylin, dehydrated, treated with
xylene, and mounted. CIP2A protein levels were scored as
described [29].
Agents
Rabdocoetsin B was extracted from Rabdosia coetsa by Professor
Han-Dong Sun. The 3-(4, 5)-dimethylthiahiazo (-z-y1)-3, 5-di-
Figure 4. Rabdocoetsin B induces down-regulation of CIP2A. (A): Structure of rabdocoetsin B. (B): A549 cells were treated with rabdocoetsin B
(RdB) at various concentrations for 48 h. Western blots were used to detect the expression of CIP2A protein (upper panel) and CIP2A protein
expression were quantified and normalized against b-actin expression (lower panel) (C): H1975 cells were treated with rabdocoetsin B at various
concentrations for 24 h. Western blots were used to detect the expression of CIP2A protein (upper panel) and CIP2A protein expression were
quantified and normalized against b-actin expression (lower panel) (D): A549 cells were treated with rabdocoetsin B at various concentrations for
48 h, and the mRNA expression of CIP2A was analyzed using real-time RT-PCR.
doi:10.1371/journal.pone.0020159.g004
CIP2A in Lung Cancer
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(Solon, OH). PE Annexin V-7AAD Apoptosis Detection kit was
obtained from BD Biosciences (San Jose, CA, USA).
Antibodies
The antibodies used in this study were as follows: anti-b-Actin
(Sigma); anti-casp-9 (C9), anti-casp-8 (1C12); anti-PARP, anti-
phospho-p44/42 MAPK, anti-EGFR, anti-Src and anti-b-catenin
(Cell signaling), anti-CIP2A (2G10-3B5), anti-pAKT and ATK
(Santa Cruz Biotechnology); anti-ERK2 (Abcam); anti-PCNA
(Abmart); anti-rabbit or anti-mouse HRP-conjugated secondary
antibody (Pierce); Rabbit Polyclonal anti-CIP2A (Novus Biologi-
cals, Inc). Detection was performed by using a Chemiluminescent
Western detection kit (Cell Signaling).
Figure 5. Downregulation of CIP2A leads to decrease of phosphorylated Akt in lung cancer cells. (A): A549 cells were transfected
with NC or CIP2A-specific siRNA for 72 h, and the expression of indicated proteins were detected using Western blots. (B and C): A549 (B) and
H1975 cells (C) were treated with rabdocoetsin B (RdB) at indicated concentrations for 48 and 24 h, respectively, and Western blots were
performed to analyze the expression of proteins indicated. (D and E): H1975 (D) and A549 (E) cells were treated with rabdocoetsin B (RdB) for
indicated time points, and Western blot analysis was carried out with antibodies specific for the indicated proteins. b-actin is used as a loading
control.
doi:10.1371/journal.pone.0020159.g005
CIP2A in Lung Cancer
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The lung cancer lines NCI-H1975 and A549 and human
embryonic kidney HEK-293 cells were obtained from the
American Tissue Culture Collection (ATCC) and human
embryonic lung fibroblast MRC-5 cells were purchased from the
Cell Resource Center, Chinese Academy of Medical Sciences
(Beijing). Normal human bronchial epithelial cells (HBEpiC,
Catalog Number: 3210) were purchased from ScienCell (ScienCell
Research Laboratories, San Diego, California). Human lung
squamous carcinoma cell lines L78 and highly metastatic large-cell
lung cancer cell lines 95D were obtained from the Cell bank of
Chinese Academy of Sciences (Shanghai), and human embryonic
lung fibroblast HLF cells were purchased from Kenqiang
Instrument Co., Ltd (Shanghai, China). BEAS-2B bronchial
epithelial cells were provided by Professor Hongbin Ji at Shanghai
Institute for Biological Sciences, Chinese Academy of Sciences.
A549, HLF and BEAS-2B cells were cultured in Dulbecco
modified Eagle medium (DMEM) containing 10% fetal bovine
serum (FBS; Gibco/BRL, Grand Island, NY), 100 U/ml penicil-
lin, 100 mg/ml streptomycin. HBEpiC cells were cultured in a
serum-free Bronchial Epithelial Cell Medium (BECM, Cat.
No. 3211, ScienCell Research Laboratories) containing essential
and non-essential amino acids, vitamins, hormones, growth factors
and trace minerals. L78, 95D and NCI-H1975 cells were cultured
in RPMI 1640 supplemented with 10% fetal bovine serum (FBS;
Gibco/BRL, Grand Island, NY), 100 U/ml penicillin, 100 mg/ml
streptomycin. MRC-5 cells were cultured in MEM/EBSS medium
supplemented with non-essential amino acids, 10% fetal bovine
serum (FBS; Gibco/BRL, Grand Island, NY), 100 U/ml penicillin
and 100 mg/ml streptomycin.
Assessment of cell proliferation and apoptosis
Cells were treated with Rabdocoetsin B for indicated concen-
tration and time points. Cell proliferation was determined using
MTT assay. Cell viability was estimated by trypan blue dye
exclusion. Externalization of phosphatidylserine was tested using a
Figure 6. Rabdocoetsin B exhibits anti-tumor activity in lung cancer cells. (A): Lung cancer cells were treated with increasing concentrations
of Rabdocoetsin B (RdB) (from 1 mMt o1 0mM) and cell viability was measured 48 h by the MTT assay. (B): the IC50 of cells treated with rabdocoetsin
B. (C): Rabdocoetsin B induces apoptosis of A549 cells, assayed by flow cytometry. (D and E): Western blots were performed to detect the expression
of apoptosis regulators in A549 (D) and H1975 cells (E).
doi:10.1371/journal.pone.0020159.g006
CIP2A in Lung Cancer
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San Jose, CA) according to manufacturer’s instruction.
Quantitative real-time PCR
Quantitative real-time PCR was performed in CFX
TM96 Real
Time System (Bio-Rad) using SYBRH Premix Ex Taq
TM(Perfect
Real Time) (TaKaRa Code: DRR041) according to the manu-
facturer’s instruction. Primers for CIP2A and Actin were as
follows: CIP2A: forward sequence, 59-TGCGGCACTTGGAG-
GTAATTTC-39, reverse sequence, 59-AGCTCTACAAGGCA-
ACTCAAGC-39; Actin: forward sequence, 59-ATCGTCCA-
CCGCAAATGCTTCTA-39, reverse sequence, 59-AGCCATGC-
CAATCTCATCTTGTT-39. Levels of CIP2A mRNA were
expressed as the ratio versus actin based on the CT values.
siRNA assays
Using HiPerFect Transfection Reagent (Qiagen, Crawley, UK)
according to the manufacturer’s protocol, cells were transfected
with 100 nM double-stranded siRNA oligonucleotides [3]. The
siRNA sequences were 59-CUGUGGUUGUGUUUGCACUTT-
39 (CIP2A siRNA1), 59-ACCAUUGAUAUCCUUAGAATT-39
(CIP2A siRNA2) [3], and 59-UUCUCCGAACGUGUCAC-
GUTT-39 (negative control (NC) siRNA).
Clonogenic assay
For foci formation, A549 or L78 cells transfected with negative
control or CIP2A-specific siRNA were seeded in triplicate onto
35 mm plates (300 cells per plate). After 14 days of culturing, cells
were stained with Giemsa and clones containing more than 50
cells were counted. For soft-agar colony formation assay, cells were
suspended in 1 ml DMEM (for A549 cells) or RPMI 1640 (for L78
cells) containing 0.3% low-melting-point agarose (Amresco, Solon,
OH) and 10% FBS and plated on a bottom layer containing 0.6%
agarose in 35 mm plat (1,000 cells/plate) in triplicate. After 2-3
weeks culturing, plates were stained with Giemsa and colonies
were counted using a light microscope.
Murine models
All animal studies were conducted according to protocols
approved by the Animal Ethics Committee of the Institute of
Zoology, Chinese Academy of Sciences, with the approval ID of
AEC2010070202. All mice used in this study were bred and
maintained in a specific pathogen-free environment. Nude mice
(n=8) were injected subcutaneously with A549 cells (4610
6)
transfected with NC or CIP2A-specific siRNA into right and left
flanks respectively, and tumor was calculated as described [12].
Statistical analysis
Differences between data groups were evaluated for significance
using Student t-test of unpaired data, x
2 test or one-way analysis of
variance and Bonferroni post-test. The tumor volume was
analyzed with one-way ANOVA and independent sample t test
using the software SPSS 12.0 for Windows (Chicago, IL). The
association between CIP2A high expression and clinicopatholog-
ical feature was assessed using either x
2 test or the Fisher exact test,
and a backward stepwise multivariate logistic regression analysis
was carried out to investigate the most significant variables related
to CIP2A over-expression after adjustment. P values ,.05 were
considered statistically significant. All experiments were repeated
at least three times and the data were presented as the mean6SD
unless noted otherwise.
Supporting Information
Figure S1 The effects of CIP2A depletion on the L78
cells’ growth and trasnsformation. (A): Western blot analysis
of CIP2A protein expression in L78 cells 72 h after transfection
with NC or CIP2A-specific siRNA. (B and C): Flat plate clone
formation assay for clonogenic activity of L78 cells 72 h after
transfection with NC or CIP2A-specific siRNA. (B): Representa-
tive light microscopy images. (C): Quantitation of foci counting.
Shown is mean+SD of three independent experiments. (D and E):
Soft-agar colony formation assay of L78 cells transfected with NC
or CIP2A-specific siRNA. (D): Representative light microscopy
images. (E): Quantitation of foci counting.
(TIF)
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